MD Research's  Instablog

MD Research
Send Message
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach. I provide consulting to clients, both the retail and... More
My company:
Vincata Enterprises LLC
My blog:
Retail Investor 360
  • Amidst Whirlwind Of Opinions From Tourbillon MannKind Shareholders Remain Strong 4 comments
    Jul 31, 2014 6:11 PM | about stocks: MNKD

    Published: Thursday, 31 July 2014 03:44 Written by Doctor Hung V. Tran, MD, MS. Disclosure: I am long on MNKD.

    As the next earnings report is approaching for MannKind Corporation, loyal shareholders are anxiously waiting for the management's announcement regarding Afrezza commercialization. MannKind Corporation is a small company based in Valencia, California, with its FDA approved lead drug Afrezza indicated for diabetes mellitus treatment.

    Recent negative opinions by Tourbillon's manager, Mr. Jason Karp, during his appearance on CNBC also added stress for shareholders awaiting MannnKind's fate. While the merits of the SAC fund manager are debatable, Mr. Karp's opinions indeed had negative impact on MannKind's shares price.

    (click to enlarge)

    Source: Guru Focus

    Since the July 25th article detailing Mr. Karp's statement on a blog called Value Walk, which consistently posted negative articles on MannKind the stock seemed to lost its steam and traded 10 percent lower to close at $8.66.

    MannKind shareholders on various social media platforms, including StockTwits, Twitters, and Facebook fought hard to bring truth regarding MannKind and Afrezza.

    To continue reading the article, please click on this LINK.

    Stocks: MNKD
Back To MD Research's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (4)
Track new comments
  • Roids0777
    , contributor
    Comments (24) | Send Message
     
    good article. Nicely done.
    31 Jul 2014, 07:47 PM Reply Like
  • MD Research
    , contributor
    Comments (208) | Send Message
     
    Author’s reply » @Roids0777 Thanks!
    1 Aug 2014, 06:59 PM Reply Like
  • Wall Street Sleuth
    , contributor
    Comments (100) | Send Message
     
    Unfortunately, stocks like mnkd are vulnerable to lies and misinformation. The way to profit is to tap a small position and add as it goes down.
    1 Aug 2014, 08:45 AM Reply Like
  • MD Research
    , contributor
    Comments (208) | Send Message
     
    Author’s reply » @Wall Street Sleuth I concurred, that's a good strategy!
    1 Aug 2014, 07:00 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.